Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT 1A receptor agonist, using a behavioural model in rats

By Vis P.   Della Pasqua O.   Kruk M.   Martin D.   Mocaer E.   Danhof M.   Jochemsen R.  

European Journal of Pharmacology, Vol. 414, Iss. 2, 2001-03 ,pp. : 233-243

Elsevier

Access to resources Recommend Favorite

The anxiolytic effects of flesinoxan, a 5-HT 1A receptor agonist, are not related to its neuroendocrine effects

By Groenink L.   Van der Gugten J.   Verdouw P.M.   Maes R.A.A.   Olivier B.  

European Journal of Pharmacology, Vol. 280, Iss. 2, 1995-07 ,pp. : 185-193

Elsevier

Access to resources Recommend Favorite

Differential effects of the 5-HT 1A receptor agonist flesinoxan given locally or systemically on REM sleep in the rat

By Monti J.M.   Jantos H.  

European Journal of Pharmacology, Vol. 478, Iss. 2, 2003-10 ,pp. : 121-130

Elsevier

Access to resources Recommend Favorite

Effect of sustained administration of the 5-HT 1A receptor agonist flesinoxan on rat 5-HT neurotransmission

By Haddjeri N.   Ortemann C.   de Montigny C.   Blier P.  

European Neuropsychopharmacology, Vol. 9, Iss. 5, 1999-09 ,pp. : 427-440

Elsevier

Access to resources Recommend Favorite

Flesinoxan treatment reduces 5-HT 1A receptor mRNA in the dentate gyrus independently of high plasma corticosterone levels

By Sibug R.M.   Compaan J.C.   Meijer O.C.   Van der Gugten J.   Olivier B.   De Kloet E.R.  

European Journal of Pharmacology, Vol. 353, Iss. 2, 1998-07 ,pp. : 207-214

Elsevier

Access to resources Recommend Favorite